II. Epidemiology
-
Prevalence: Estimated 79 million in U.S. are HPV infected (2013)
- HPV Lifetime Prevalence in those with at least one sexual partner: 85% in women, 91% in men
- Peak HPV Prevalence: 20-25 years in women, 25 to 35 years in men
- Incidence: 14 million new infections U.S. per year (2013)
- Women have been primary initial target for cervical Cancer Prevention
- High risk HPV Prevalence in U.S. females ages 15 to 19 years old: 20-25%
- Men have been added in U.S. as of 2012 for HPV-related Cancer Prevention
- Annual number of new cases of HPV-related cancers in american men: 9810
- HPV-related cancers in males include oral cavity, oropharynx, Larynx, anal cancer, penis
III. Risk Factors
- Anogenital HPV Infection
- Early sexual contact (younger age of onset)
- Multiple sexual partners
- Other Sexually Transmitted Infections
- HIV Infection
- Immunocompromised State
- No barrier protection during sex
- Persistent HPV infection (risk for progression)
- Alcohol use (oral and Genital HPV)
- Tobacco Abuse (oral and Genital HPV)
IV. Types: High Risk for Anogenital Neoplasia and Cancer
- HPV 16 (causes 50% of all Cervical Cancers, usually squamous cell cancers)
- HPV 18 (causes 20% of all Cervical Cancers, usually adenocarcinoma)
- HPV 31 (causes 4% of all Cervical Cancers)
- Other higher risk HPV types
- HPV 33, 35, 39, 45
- HPV 51, 52, 56, 58, 59, 66, 68
V. Types: Low Risk HPV
- Cutaneous Warts (Common Warts)
- HPV 1
- HPV 2
- HPV 4
- Palmoplantar Warts
- HPV 1
- HPV 2
- HPV 27
- HPV 57
- Mucosal Warts (responsible for 95% of Genital Warts)
- HPV 6
- HPV 11
VI. Pathophysiology
- Group of over 200 DNA viruses that infect epithelial cells (skin and mucosa)
- Transmission of HPV from Genital Warts
- HPV is very contagious due to high viral loads
- Transmission rate: 65%
- Incubation Period duration following exposure: 3 weeks to 8 months
- Oral transmission occurs at a lower rate
- Perinatal transmission is rare
- Nearly one third of Genital Warts contain both High risk and low risk HPV types
- Course
- Spontaneous clearance of high risk or low risk HPV within 2 years for 90% of patients
- Genital Warts clear spontaneously in up to 30% of cases within 4 months
- Genital Warts clear on average within 6 months with treatment (80% effective)
- Progression to cancer is a small percentage of overall HPV cases and typically develops over years to decades
- Cancer development
- HPV invades human cells
- HPV DNA integrates into host cell
- Viral oncoproteins (E6 and E7) are expressed
- Oncoproteins bind and block tumor suppression genes (TP53, RB1)
VII. Associated Conditions: Genital infections
- Caused by ~40 HPV types
- Transient HPV infection without lesions
- HPV is the most common STD in women
- Lifetime Prevalence in sexually active women: 80%
- HPV infection peaks at age 20 (and again post-Menopause in some patients)
-
Genital Warts (Condyloma acuminata)
- Lifetime Prevalence (U.S.): 1%
- Perianal warts
- Local spread from genitalia or
- Receptive anal intercourse
-
Cervical Cancer
- Caused by ~15 High Risk HPV types (see above)
- HPV positive in 90% (HPV 16 or 18 in 90%)
- CIN 1-2 typically regress spontaneously, but persistence >1-2 years are more likely to progress to CIN3
- CIN3 progresses to invasive Cervical Cancer in 12 to 30% of cases
- HPV infection precedes Cervical Cancer diagnosis by 10-20 years
- Typically diagnosed after age 40
- HPV screening for ages 30-40 has highest yield
- Genital cancers that occur less commonly
- Vaginal cancer
- Vulvar Cancer
- Anal cancer
- HPV positive in 90% (HPV 16 or 18 in 86%)
- Penile Cancer (uncircumsized men)
- HPV positive in 60% (HPV 16 or 18 in 75%)
- Other lesions associated with HPV infection
- Oral squamous cell cancer
- HPV positive in 70% (HPV 16 or 18 in >80%)
- HPV positive lesions present at younger age than HPV negative lesions
- With treatment, HPV positive lesions have higher survival rates than HPV negative lesions
- Respiratory papillomatosis (perinatal transmission)
- Oral squamous cell cancer
VIII. Associated Conditions: Non-genital
- Common Wart
- Plantar Wart
- Respiratory papillomatosis (perinatal transmission)
IX. Labs: HPV DNA testing by PCR
- Aptiva HPV - RNA (14 high risk HPV types)
- Test Sensitivity: 97.6%
- Test Specificity: 90.2%
- Cervista HPV HR - DNA (14 high risk HPV types)
- Lower Test Sensitivity (89%) than other tests
- Test Specificity: 91%
- Gives only positive or negative result (without type specific info)
- Cobas HPV - DNA (HPV 14 high risk HPV types)
- Test Sensitivity: 97.3%
- Test Specificity: 84.5%
- Hybrid Capture II (13 high risk HPV types)
- Test Sensitivity: 97.5%
- Test Specificity: 84.3%
X. Protocol: Cervical HPV Testing
XI. Prevention
-
HPV Vaccines
- See Human Papilloma Virus Vaccine (Gardasil-9)
- Most effective when administered before the onset of sexual activity
- FDA approved for ages 9 to 45 years old
- Part of Primary Series in U.S. for both genders at age 11-12 years old
-
Condoms
- Efficacy is 70% in HPV transmission prevention
-
Tobacco Cessation
- Tobacco use is associated with Genital Wart development and persistent HPV infection
-
Circumcision (routine at birth in the U.S.)
- Lower risk of HPV infection